retatrutide triple agonist clinical trial status approval: FDA status, results, and when it could be available hormone receptor retatrutide – Triple hormone receptor agonist retatrutide – Lilly's 'triple G' agonist triumphs

Semaglutide is a GLP-1 receptor agonist that mimics the natural incretin hormone to reduce appetite, slow gastric emptying, and improve blood sugar regulation

However, GIPR agonism can potentially decrease the nauseous effects of GLP1 agonism by inhibiting area postrema inhibitory neurons

It also reduces caloric intake by slowing gastric emptying and activating central satiety circuits in the brainstem and hypothalamic nuclei (16)

Where Cagrilintide Fits in the Broader Peptide Research Landscape The metabolic peptide research field in 2026 includes several active research threads: Single agonists semaglutide is the reference compound